Company / SG&A Expense
Marker Therapeutics, Inc. SG&A Expense History
FY2018-FY2021 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$12.9M
FY2021
5-year range
$6.4M / $12.9M
FY2018-FY2021
Trend
+29.5%
vs FY2020
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Increased from $6M to $13M over the past 3 years.
Based on SEC 10-K filings.
$13M in FY2021.
Increased from $6M to $13M over the past 3 years.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +26.3%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of +26.3%, indicating consistent growth.
- In FY2021, sg&a expense increased 29.5% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -5.64 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2021 | $12.9M | +29.5% |
| FY2019 | $10.0M | +55.6% |
| FY2018 | $6.4M | - |
As of FY2021 · SEC 10-K · Updated Jun 28, 2026